Jason Gaglia, MD
Enriched profileAssistant Professor of Medicine, Harvard Medical School; Section Head, Clinical, Behavioral, and Outcomes Research, Joslin Diabetes Center · Joslin Diabetes Center
Jason Gaglia is Assistant Professor of Medicine, Harvard Medical School; Section Head, Clinical, Behavioral, and Outcomes Research, Joslin Diabetes Center at Joslin Diabetes Center. OpenAlex indexes 76 publications with 11,619 citations (h-index 38); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jason L. Gaglia, MD, is Assistant Professor of Medicine, Harvard Medical School at Joslin Diabetes Center (Harvard Medical School affiliate), Boston, MA. The public record shows 76 publications with 11,619 citations (h-index 38), centered on Diabetes Management and Research, Pancreatic function and diabetes, Diabetes and associated disorders. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 9 companies, 1 NIH-funded awards (2022–2025).
- Most recent indexed publication: 2026 · Diabetes
- Top research focus: Diabetes Management and Research
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 45.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- A Study of GNTI-122 in Adults Recently Diagnosed With T1D
Sponsor: GentiBio, Inc
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- GENZYME CORPORATIONProgram year20251 payment
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year202410 payments$281,750openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
85.1%GLP-1 receptor agonist25.9%Mounjaro71%Ozempic29%Part D<11 patientsBiguanide (metformin)19.5%Metformin Hcl Er100%Part D≥12 patientsHormonal (systemic)
8.6%l-Thyroxine8.6%Levothyroxine Sodium100%Part D<11 patientsCardiovascular
6.3%Statin6.3%Rosuvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:
- Early detection of type 1 diabetes via Exosome Technology with Optoelectronics Lab-on-chip: EXTOL
Brigham and Women'S Hospital
FY2025$724,514R01DK133864 - Early detection of type 1 diabetes via Exosome Technology with Optoelectronics Lab-on-chip: EXTOL
Brigham and Women'S Hospital
FY2024$728,967R01DK133864 - Early detection of type 1 diabetes via Exosome Technology with Optoelectronics Lab-on-chip: EXTOL
Brigham and Women'S Hospital
FY2023$733,231R01DK133864
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.
Diabetes care
Review2025 - 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.
Diabetes care
Review2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jason-gaglia-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jason-gaglia-md-mmsc-4b5ba4198
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
thesugarscience.podbean.com/e/heard-on-the-street-jason-gaglia-md-joslin-diabetes-center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thesugarscience.podbean.com ↗ - LinkedIn
LinkedIn profile: Jason Gaglia, MD, MMSc, Joslin Diabetes Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center / Joslin Diabetes Center Joint Program
2006provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- MD
Harvard Medical School (magna cum laude, via Harvard/MIT Health Sciences and Technology Program)
2001provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →joslin.org ↗
- Board Certified
American Board of Internal Medicine – Endocrinology, Diabetes and Metabolism
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Member
American Diabetes Association Professional Practice Committee, Standards of Care in Diabetes
2026provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →diabetesjournals.org ↗ - Director
Type 1 Diabetes TrialNet Clinical Center at Joslin Diabetes Center; Clinical Lead, Stage 1 T1D clinical program, T1D TrialNet (NIH-funded network)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →immuthera.bio ↗ - Co-director
Joslin Clinical Translational Research Center Core; Manager, Hood Center (childhood diabetes prevention)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →immuthera.bio ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Member
Scientific Advisory Board, Immuthera
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →immuthera.bio ↗
Media & interviews
press, podcasts and appearances- CME lecture: "Screening, Monitoring, and Early Interventions in Type 1 Diabetes"
GWU School of Medicine Endocrinology Grand Rounds 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cme.smhs.gwu.edu ↗ - Podcast: "Heard on the Street: Jason Gaglia, MD, Joslin Diabetes Center"
TheSugarScience Podcast, discussing dendritic cell therapy AVT001 poster from ADA 2023
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thesugarscience.podbean.com ↗ - Panelist
DiaTribe Foundation panel "Managing Hypoglycemia and Hypo Unawareness: Is Technology Enough?" moderated by Dr. Alan Moses
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →diatribe.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Lloyd Aiello, MD, PhD
Joslin Diabetes Center
Sylvia Rosas, MD
Joslin Diabetes Center
Mary Horlick
Joslin Diabetes Center
Osama Hamdy, MD, PhD
Joslin Diabetes Center